IQVIA

Novotech Announces Key Leadership Appointments: Rick Farris, North America Managing Director and Dr. David Ng, Global Vice President of Biometrics and Data

Retrieved on: 
Friday, October 13, 2023
Partnership, WuXi AppTec, Drug development, IQVIA, Data management, Growth, Biometrics, Biostatistics, Automotive Executive of the Year Award, Rare, PPD, History, ChromeOS, Thermo Fisher Scientific, Wuxi, Ng, Fine chemical, Nursing, Management

Dr. David Ng a specialist in biostatistics and biometrics has assumed the position of Global Vice President for Biometrics and Data Management.

Key Points: 
  • Dr. David Ng a specialist in biostatistics and biometrics has assumed the position of Global Vice President for Biometrics and Data Management.
  • “Rick has led operations teams and played a key role in establishing global project management capabilities.
  • I am joining at an exciting time, where Novotech is further expanding the North America operations to serve the innovative biotech market,” commented Rick.
  • Dr. David Ng’s appointment as Novotech’s Global VP of Biometrics and Data Management brings over three decades of biostatistics, data management, and strategic leadership.

Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)

Retrieved on: 
Tuesday, October 17, 2023
III, European, Prescription, IQVIA, Cosmo, Ageing, Safety, Sun Pharma, EMA, FDA, Marketing Authorisation Application, European Medicines Agency, Marketing, IGA, Acne, XETRA, Dermatology, Patient, C43, MAA, Pharmaceutical industry, Medical device, EU

This filing marks a significant milestone in pipeline progression, as approval will open the substantial EU market to already selected, high-standing partners.

Key Points: 
  • This filing marks a significant milestone in pipeline progression, as approval will open the substantial EU market to already selected, high-standing partners.
  • Cosmo has officially submitted the Marketing Authorisation Application (MAA) for its innovative acne treatment clascoterone 1% cream (Winlevi®) to the European Medicine Agency (EMA) through the centralized procedure, aimed at obtaining a single Marketing Authorization for the product in the European Union.
  • The EMA's rigorous evaluation process will assess the product's safety, quality, and efficacy, ultimately determining its suitability for approval within the European market.
  • This submission to the EMA is a pivotal step forward in our mission as well as a testament to our ongoing commitment to innovation.

IQVIA and CEPI Collaborate to Strengthen Global Research Preparedness to Advance the 100 Days Mission

Retrieved on: 
Wednesday, October 11, 2023
COVID-19, Infectious Diseases, Clinical Trials, Health Technology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Disease, Infection, NYSE, Global Public Health (journal), Research, Vaccine, IQV, Surge (drink), CEPI, Pandemic, G7, G20, Developing country, Epidemic, Low, Coalition for Epidemic Preparedness Innovations, Coalition, Patient, Pharmaceutical industry, IQVIA

IQVIA, (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services, and The Coalition for Epidemic Preparedness Innovations (CEPI) today announced a strategic collaboration to advance the 100 Days Mission.

Key Points: 
  • IQVIA, (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services, and The Coalition for Epidemic Preparedness Innovations (CEPI) today announced a strategic collaboration to advance the 100 Days Mission.
  • In conjunction with national and regional collaborators, CEPI and IQVIA will aim to enhance the world’s preparedness to rapidly conduct life-saving clinical research for vaccines and other biological countermeasures against emerging infectious diseases.
  • This clinical research preparedness has been identified as a key enabler of the 100 Days Mission : a goal spearheaded by CEPI, and backed by the G7 and G20, which aims to accelerate the time taken to develop safe, effective, globally accessible vaccines against emerging disease outbreaks to within 100 days.
  • IQVIA’s collaboration with CEPI will support the 100 Days Mission in delivering transformative healthcare worldwide.

IQVIA to Announce Third-Quarter 2023 Results on November 1, 2023

Retrieved on: 
Monday, October 9, 2023
Science, Other Science, Biotechnology, Pharmaceutical, Health, Health Technology, Clinical Trials, Other Health, ID, IQV, NYSE, Webcast, Wright Investors' Service Holdings, Inc., IQVIA

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2023 financial results before the market opens on Wednesday, November 1, 2023.

Key Points: 
  • IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2023 financial results before the market opens on Wednesday, November 1, 2023.
  • The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day.
  • The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com .

Contract Research And Manufacturing Services (CRAMS) Global Market Research Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023
Software, Research, Pharmaceutical, Medical Devices, Technology, Artificial Intelligence, Other Manufacturing, Clinical Trials, Science, Biotechnology, Manufacturing, Health, Acquisition, Drug development, IQVIA, Data management, Cancer, Thermo Fisher Scientific, Diabetes, Contract research organization, Artificial intelligence, Ageing, Innovation Center for Artificial Intelligence, Clinical trial, PPD, Alzheimer's disease, Fine chemical, Pharmaceutical industry

The "Contract Research And Manufacturing Services (CRAMS) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Contract Research And Manufacturing Services (CRAMS) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • This elevates the demand for diverse drugs and therapies, spotlighting the indispensable role of contract research and manufacturing services.
  • North America was the largest region in the contract research and manufacturing services (CRAMS) market in 2022.
  • The countries covered in the contract research and manufacturing services (CRAMS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

PADAGIS ANNOUNCES THE LAUNCH OF BRINZOLAMIDE OPHTHALMIC SUSPENSION WITH CGT EXCLUSIVITY

Retrieved on: 
Friday, October 13, 2023
IOP, Glaucoma, IQVIA, Patient, Ocular hypertension, CGT, Pharmaceutical industry, Mobile phone

Azopt® Ophthalmic Suspension is indicated to decrease elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma, as monotherapy in patients unresponsive to betablockers or in patients in whom beta-blockers are contraindicated, or as adjunctive therapy to betablockers.

Key Points: 
  • Azopt® Ophthalmic Suspension is indicated to decrease elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma, as monotherapy in patients unresponsive to betablockers or in patients in whom beta-blockers are contraindicated, or as adjunctive therapy to betablockers.
  • Annual market sales for Azopt® were approximately $74 million in the 12 months ended August 2023 as measured by IQVIA.
  • Padagis President, Pamela Hoffman, stated, "This launch and its accompanying CGT exclusivity demonstrates the ability of the Padagis team to bring complex generic products to the markets that need them.
  • The Padagis team continues to leverage our unique and specialized technical and commercial capabilities to deliver important products to our customers and patients."

Healthcare BPO Market size worth USD 747.81 Billion, Globally, by 2028 at 10.61% CAGR: Verified Market Research®

Retrieved on: 
Friday, October 13, 2023
Patent, Hospital, Geography, Health care, IBM, USD, Bank statement, Accenture, Greg Lindberg, Diversified Pharmaceutical Services, Freedom of Establishment and Freedom to Provide Services in the European Union, Insurance, Health, BPO, Medicare, Growth, UnitedHealth Group, Accounting, National Society of Certified Healthcare Business Consultants, Medical tourism, Research, Retail, Pharmaceutical industry, IQVIA, Parexel

JERSEY CITY, N.J., Oct. 13, 2023 /PRNewswire/ -- The Global Healthcare BPO Market is projected to grow at a CAGR of 10.61% from 2021 to 2028, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 211.65 Billion in 2020 and is expected to reach USD 747.81 Billion by the end of the forecast period.

Key Points: 
  • The " Global Healthcare BPO Market Size By Type, By Delivery Mode, By Geographic Scope And Forecast " report has been published by Verified Market Research®.
  • The report provides an in-depth analysis of the global Healthcare BPO Market, including its growth prospects, market trends, and market challenges.
  • To get market data, market insights, financial statements and a comprehensive analysis of the Global Healthcare BPO Market, please Contact Verified Market Research® .
  • Based on the research, Verified Market Research® has segmented the global Healthcare BPO Market into Provider Service, Payer Service, Pharmaceutical Service, And Geography.

Healthcare BPO Market size worth USD 747.81 Billion, Globally, by 2028 at 10.61% CAGR: Verified Market Research®

Retrieved on: 
Friday, October 13, 2023
Patent, Hospital, Geography, Health care, IBM, USD, Bank statement, Accenture, Greg Lindberg, Diversified Pharmaceutical Services, Freedom of Establishment and Freedom to Provide Services in the European Union, Insurance, Health, BPO, Medicare, Growth, UnitedHealth Group, Accounting, National Society of Certified Healthcare Business Consultants, Medical tourism, Research, Retail, Pharmaceutical industry, IQVIA, Parexel

JERSEY CITY, N.J., Oct. 13, 2023 /PRNewswire/ -- The Global Healthcare BPO Market is projected to grow at a CAGR of 10.61% from 2021 to 2028, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 211.65 Billion in 2020 and is expected to reach USD 747.81 Billion by the end of the forecast period.

Key Points: 
  • The " Global Healthcare BPO Market Size By Type, By Delivery Mode, By Geographic Scope And Forecast " report has been published by Verified Market Research®.
  • The report provides an in-depth analysis of the global Healthcare BPO Market, including its growth prospects, market trends, and market challenges.
  • To get market data, market insights, financial statements and a comprehensive analysis of the Global Healthcare BPO Market, please Contact Verified Market Research® .
  • Based on the research, Verified Market Research® has segmented the global Healthcare BPO Market into Provider Service, Payer Service, Pharmaceutical Service, And Geography.

Novotech Appoints Dr. Judith Ng-Cashin as Chief Medical Officer to Drive Global Medical Services

Retrieved on: 
Tuesday, October 3, 2023
Health, GSK, Anzac of the Year Award, IQVIA, Collaboration, Lead, Coronavirus Scientific Advisory Board, Infection, CMO, Quality, Syneos Health, Patient, Hematology, Rare, Therapy, DIA, AOBiome, Safety, Fine chemical, Medical device, Pharmaceutical industry, Dermatology, Stiefel

BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Novotech , the leading Asia Pacific centred biotech CRO with global execution capabilities, announced today the appointment of Dr. Judith Ng-Cashin as Chief Medical Officer (CMO).

Key Points: 
  • BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Novotech , the leading Asia Pacific centred biotech CRO with global execution capabilities, announced today the appointment of Dr. Judith Ng-Cashin as Chief Medical Officer (CMO).
  • Dr. Ng-Cashin, who brings 20 years of international pharmaceutical, biotech, and CRO experience including CMO roles, will be based in the US and lead Novotech’s global Medical Services team.
  • According to Novotech CEO, Dr. John Moller, the appointment of such a high calibre medical executive as Dr. Ng-Cashin is a significant advancement for Novotech and its biotech clients.
  • Dr. Ng-Cashin’s senior leadership roles have included Eagle Pharmaceuticals as Chief Medical Officer and Head of R&D, AOBiome Therapeutics as CMO, and Syneos Health as Chief Scientific Officer.

IQVIA Builds on its Strategic Collaboration with argenx to Provide Safety Systems and Services

Retrieved on: 
Tuesday, October 3, 2023
Technology, Research, Clinical Trials, Professional Services, Software, Biotechnology, Health, Data Analytics, Science, IQVIA, Safety, PV, Patient, IQV, NYSE, Autoimmunity, Pharmaceutical industry, Renewable energy

IQVIA’s integrated PV services and technology platforms will support argenx to enable efficient integration of safety data and adverse event identification and reporting, ultimately facilitating the delivery of new therapies to patients.

Key Points: 
  • IQVIA’s integrated PV services and technology platforms will support argenx to enable efficient integration of safety data and adverse event identification and reporting, ultimately facilitating the delivery of new therapies to patients.
  • The integration of safety data, operational processes and business acumen will support argenx to scale its PV and safety organization alongside future company growth.
  • This builds on IQVIA and argenx’s existing collaboration which focuses on the accelerated expansion of clinical development and commercialisation of new indications.
  • “IQVIA is well positioned to support biotech clients such as argenx through our extensive portfolio of services and technology capabilities,” said Alistair Grenfell, President Europe, Middle East, Africa and South Asia, IQVIA.